All Immunology articles – Page 5
-
NewsNew genetic discovery offers hope for arthritis drug development
York University researchers have discovered a genetic mutation in the TRAF1 protein that dramatically reduces inflammation, offering a potential breakthrough in rheumatoid arthritis treatment.
-
NewsScientists identify key protein fuelling autoimmune attacks
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
-
NewsThe immune cells that fuel food allergies
A new study reveals how specific immune cells contribute to the exaggerated immune response in food allergies, offering hope for improved treatments in the future.
-
NewsNew painless vaccine technology targets viruses
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
-
NewsInnovative lupus treatment under investigation at Virginia Tech
A Virginia Tech student is investigating new treatments for lupus, an autoimmune disease that affects millions worldwide.
-
NewsNew research shows way to bypass immunotherapy resistance
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
-
ArticleLeveraging agonist antibodies to address immunological diseases
Therapeutic antibodies play a key role in addressing unmet medical needs. Here, Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases, helping to mediate interactions between circulating immune cells and influencing the intensity and ...
-
ReportBeyond the lab: antibodies
Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscience, showcasing how advancements are redefining the precision and potential of antibody-based therapies.
-
NewsNew link found between immune system and neurological disease
Findings show that alpha-synuclein and an immune response are required for Lewy body formation, in an effect specific to dopaminergic neurons.
-
Article’1104: tackling the root cause of allergic disease
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings. ...
-
ArticleRestoring TERT to attenuate ageing hallmarks
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
-
WebinarUnprecedented fragment-based screening using Spectral Shift for GPCRs
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
-
NewsAdvancing HIV treatment with a small molecule inhibitor
The new study demonstrated that a small molecule inhibitor, BLZ945, could be used as a potential therapeutic to achieve viral clearance.
-
NewsMini-lungs enable breakthroughs in SARS-CoV-2 research
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
-
NewsImproving vaccine responses by targeting IL-10
In an animal model, scientists have demonstrated that targeting Interleukin-10 during vaccine delivery enhances the vaccine’s ability to protect against infection.
-
ArticleTreating immune-mediated diseases with nanoparticles
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.
-
WhitepaperPoster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
-
WhitepaperPoster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
-
NewsXCL1 could mitigate psychiatric condition risk in offspring
Adult anxious behaviour in offspring may be related to the early life proinflammatory state caused by the absence of elevated XCL1.
-
ArticleBreaking resistance – the future of immunotherapy in oncology
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.